A5009297502- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Boron Compounds in Chemistry
- Medical Imaging Techniques and Applications
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Ovarian cancer diagnosis and treatment
- Nanoparticle-Based Drug Delivery
- Radiomics and Machine Learning in Medical Imaging
- Protein Degradation and Inhibitors
- DNA Repair Mechanisms
- Endometrial and Cervical Cancer Treatments
- Cancer Mechanisms and Therapy
- Chromatin Remodeling and Cancer
- Orthopedic Infections and Treatments
- Medical Imaging and Pathology Studies
- Cervical Cancer and HPV Research
- Nanoplatforms for cancer theranostics
- Microtubule and mitosis dynamics
- Uterine Myomas and Treatments
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Biochemical and Molecular Research
- CRISPR and Genetic Engineering
- Menopause: Health Impacts and Treatments
University of Pennsylvania
2020-2023
Cancer Research Center
2020-2023
Hospital of the University of Pennsylvania
2023
California University of Pennsylvania
2020
Yale University
2013-2019
Yale Cancer Center
2014
Aims: To compare baseline risk factors for type 1 vs. 2 endometrial cancers and analyze these association with overall survival time to recurrence. Methods: Retrospective review of 816 consecutive cancer cases was conducted diagnosis from January 2005 December 2010 clinical course until 2016. Risk factors, treatment, recurrence, death were compared using sample t tests, χ2 test Cox Regression models. Results: There 550 266 cancer. Patients disease older (p < 0.001), less obese = 0.03),...
PARP inhibitors exploit synthetic lethality to target epithelial ovarian cancer (EOC) with hereditary BRCA mutations and defects in homologous recombination repair (HRR). However, such an approach is limited a small subset of EOC patients compromised by restored HRR due secondary genes. Here, it was demonstrated that triapine, small-molecule inhibitor ribonucleotide reductase, enhances the sensitivity wild-type cells olaparib topoisomerase II etoposide. Triapine abolishes olaparib-induced...
Abstract Purpose: Platinum and PARP inhibitors (PARPi) demonstrate activity in breast ovarian cancers, but drug resistance ultimately emerges. Here, we examine B7-H4 expression primary recurrent high-grade serous carcinoma (HGSOC) the of a B7-H4-directed antibody–drug conjugate (B7-H4-ADC), using pyrrolobenzodiazepine-dimer payload, PARPi- platinum-resistant HGSOC patient-derived xenograft (PDX) models. Experimental Design: was quantified by flow cytometry IHC. B7-H4-ADC efficacy tested...
Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) epithelial ovarian cancer (EOC). The objective of this study was evaluate the efficacy small molecule inhibitor triapine disrupt HRR and sensitise BRCA wild-type EOC cells platinum-based combination therapy vitro vivo. sensitivity olaparib, cisplatin, carboplatin, doxorubicin, etoposide with evaluated by clonogenic survival assays. effects on activity were measured a DR-GFP...
Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation AKT pathway promotes platinum while inhibition sensitizes chemoresistant cells. Patients with BRCA mutant EOC, and thus defect homologous recombination (HR) repair pathway, demonstrate greater clinical response to olaparib therapy than patients wild-type EOC. MK-2206, an allosteric inhibitor phosphorylation, variety cell types various anticancer agents currently undergoing phase II trials...
Background Nelfinavir (NFV), an HIV‐1 protease inhibitor, has been shown to sensitize cancer cells chemoradiation (CRT). The objectives of this phase 1 trial were evaluate safety and identify the recommended 2 dose NFV added concurrent CRT for locally advanced cervical cancer. Methods Two levels evaluated: 875 mg orally twice daily (dose level [DL1]) 1250 (DL2). was initiated 7 days before continued through completion. Toxicity, radiographic responses, pathologic responses evaluated. Serial...
This study sought to evaluate characteristics of cases free-floating tumor fragments within the lumen fallopian tubes ('floaters') on final pathology for Type I and II endometrial adenocarcinoma, including relationships with disease recurrence mortality.A single institution experience 1022 consecutive uterine cancer presenting between 2005 2010 was retrospectively reviewed, data extraction from electronic medical records. Associations floaters baseline were studied logistic regression,...
<p>Immunohistochemical analysis of PDX tumors for Ki67 after ADC treatment.</p>
<p>Individual mouse data and statistical analysis of WO-2 PDX in vivo study.</p>
<p>B7-H4 cell surface expression in lines and B7-H4-ADC cytotoxicity.</p>
<p>Individual mouse data and statistical analysis of WO-19 PDX in vivo study.</p>
<p>Individual mouse data and statistical analysis of WO-2 PDX in vivo study.</p>
<p>Statistical summary of B7-H4-ADC activity in xenograft models and breast cancer PDX models.</p>
<p>B7-H4-ADC lack of activity in B7-H4 negative cell lines.</p>
<p>Individual mouse data and statistical analysis of WO-57 PDX in vivo study.</p>
<p>Western blot analysis of B7-H4-ADC activation DNA-response pathway.</p>
<p>Representative B7-H4 immunohistochemistry.</p>